EyePoint shares plunge after DURAVYU misses key goal in wet AMD trial

What happened

EyePoint, Inc. (ticker: EYPT), a specialty pharmaceutical company focused on eye disease treatments, announced topline results from LUGANO, the first of two pivotal Phase 3 clinical trials for its drug candidate DURAVYU in wet age-related macular degeneration (AMD). The data showed that DURAVYU missed the primary endpoint, according to reporting by STAT News and AllSci.

The company's stock fell dramatically in response. Biotech news account @BiopharmIQ reported an approximate 67% single-session decline, though the price data provided shows a closing price of $5.32, down 1.48% from the previous close of $5.40—this appears inconsistent with the reported drop, possibly reflecting a later date.

EyePoint reported that 76% of DURAVYU patients were supplement-free up to Week 32, and 94% received zero or one supplement in the same period, per the company's press release. However, the primary endpoint was not met, and the company said the miss was tied to nine of 211 DURAVYU patients who lost at least 15 letters of vision from causes it described as unrelated to wet AMD, as noted by AllSci and STAT News.

STAT News reported that investors were not convinced by EyePoint's explanation for the failure.

Why it matters

DURAVYU is a key pipeline asset for EyePoint, a mid/small-cap company. A failed pivotal readout in a major indication like wet AMD can significantly impair the company's valuation and future prospects, as reflected in the sharp market reaction.

The LUGANO trial is the first of two pivotal studies; the outcome could affect the development path for DURAVYU and the company's overall strategy.

What this means

A pivotal Phase 3 trial is a large, late-stage study designed to provide the primary evidence of a drug's efficacy and safety needed for regulatory approval. Missing the primary endpoint means the trial did not achieve its main goal—in this case, presumably demonstrating that DURAVYU is non-inferior or superior to the standard treatment, aflibercept, in improving or maintaining vision.

In wet AMD, patients experience abnormal blood vessel growth that leaks fluid, damaging the macula. Treatments like aflibercept are injected into the eye regularly. DURAVYU is designed as a longer-acting implant to reduce injection frequency; the trial's secondary data showed many patients needed fewer supplements, but the primary endpoint was not met.

The company attributed the miss to a subset of patients who lost vision from causes unrelated to wet AMD. However, investors often view such explanations skeptically, as the primary endpoint must be met in the intent-to-treat population. The second pivotal trial's results and any regulatory discussions will determine whether DURAVYU can still be approved.

A Form 8-K filing with the SEC, which companies use to disclose material events, may follow, but none has been cited in the sources provided.